PATENT CLAIM ANALYSIS

Application Number: 15750318
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["514", "482000"]

Abstract:
Pharmaceutical compositions for the treatment of cancer are provided. In one embodiment the composition comprises Gamitrinib and a MAPK inhibitor selected from the MAPK inhibitor is selected from RAF265, AZD6244, PLX4720, PD0325901, LGX818, MEK162, vemurafenib, trametinib and dabrafenib. Methods of treating cancer are also provided.

Claim (Index 29):
A method for diagnosing the existence or evaluating a cancer in a mammalian subject comprising identifying in the biological fluid of a mammalian subject changes in the expression of a gene product of a gene selected from Table 1 using the composition of  claim 17 , and comparing said subject's expression levels with the levels of the same gene product in the same biological sample from a reference or control, wherein changes in expression of the subject's gene product from those of the reference correlates with a diagnosis or evaluation of a disease or cancer.

Metadata:
- Claim Count in Document: 48.0
- Percentile: 88.0
- Lexical Diversity: 1.52778
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14770994', '14387735', '14147689', '12865620', '15002457']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7669625838882755
- 35 USC 102 Novelty (BERT): 0.5368687711581828
- Combined Prediction Score: 0.7439532026152663
- Mean Citation Score: 304.030938
- Max Citation Score: 382.53238
- Similarity Product: 243.5485295009828

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test